ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZVRA vs GERN // RETURN ON INVESTED CAPITAL (ROIC)

Zevra Therapeutics Inc. (NASDAQ) VS. Geron Corporation (NASDAQ) • 15-METRIC TALLY: ZVRA 4 — GERN 1
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: GERN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZVRA VS. GERN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZVRA GERN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -32.30% -20.20% -12.10 GERN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.40% -18.27% +17.87 ZVRA /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ZVRA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.0 30.6 +16.40 ZVRA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.9x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $615.2M $607.9M $7.3M ZVRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZVRA REV GERN REV ZVRA GROSS % GERN GROSS % ZVRA FCF GERN FCF
FY 2025 $0 $0 — — -$2.4M -$111.0M
FY 2024 $0 $0 — — -$69.7M -$219.3M
FY 2023 $0 $237.0K — — -$33.5M -$167.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZVRA // BETA —
GERN // BETA —